Your browser doesn't support javascript.
The dynamics of quantitative SARS-CoV-2 antispike IgG response to BNT162b2 vaccination.
Kaneko, Shun; Kurosaki, Masayuki; Sugiyama, Toru; Takahashi, Yuka; Yamaguchi, Yoshimi; Nagasawa, Masayuki; Izumi, Namiki.
  • Kaneko S; Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
  • Kurosaki M; Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
  • Sugiyama T; Department of Endocrinology and Metabolism, Musashino Red Cross Hospital, Tokyo, Japan.
  • Takahashi Y; Medical Examination Center, Musashino Red Cross Hospital, Tokyo, Japan.
  • Yamaguchi Y; Division of Clinical laboratory, Musashino Red Cross Hospital, Tokyo, Japan.
  • Nagasawa M; Division of Infection Control and Prevention, Musashino Red Cross Hospital, Tokyo, Japan.
  • Izumi N; Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
J Med Virol ; 93(12): 6813-6817, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1530183
ABSTRACT
Vaccination for SARS-CoV-2 is necessary to overcome coronavirus disease 2019 (COVID-19). However, the time-dependent vaccine-induced immune response is not well understood. This study aimed to investigate the dynamics of SARS-CoV-2 antispike immunoglobulin G (IgG) response. Medical staff participants who received two sequential doses of the BNT162b2 vaccination on days 0 and 21 were recruited prospectively from the Musashino Red Cross Hospital between March and May 2021. The quantitative antispike receptor-binding domain (RBD) IgG antibody responses were measured using the Abbott SARS-CoV-2 IgGII Quant assay (cut off ≥50 AU/ml). A total of 59 participants without past COVID-19 history were continuously tracked with serum samples. The median age was 41 (22-75) years, and 14 participants were male (23.7%). The median antispike RBD IgG and seropositivity rates were 0 (0-31.1) AU/ml, 0.3 (0-39.5) AU/ml, 529.1 (48.3-8711.4) AU/ml, 18,836.9 (742.2-57,260.4) AU/ml, and 0%, 0%, 98.3%, and 100% on days 0, 3, 14, and 28 after the first vaccination, respectively. The antispike RBD IgG levels were significantly increased after day 14 from vaccination (p < 0.001) The BNT162b2 vaccination led almost all participants to obtain serum antispike RBD IgG 14 days after the first dose.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin G / Spike Glycoprotein, Coronavirus / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Observational study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: J Med Virol Year: 2021 Document Type: Article Affiliation country: Jmv.27231

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin G / Spike Glycoprotein, Coronavirus / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Observational study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: J Med Virol Year: 2021 Document Type: Article Affiliation country: Jmv.27231